Loading...
XSHE
002742
Market cap220mUSD
Jul 10, Last price  
3.69CNY
1D
6.03%
1Q
-19.78%
Jan 2017
-66.84%
IPO
-46.23%
Name

Chongqing Sansheng Industrial Co Ltd

Chart & Performance

D1W1MN
XSHE:002742 chart
P/E
P/S
1.77
EPS
Div Yield, %
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-18.41%
Revenues
900m
-24.74%
847,780,9471,061,736,9851,173,970,2241,270,806,3931,410,854,3681,512,803,8551,902,471,9162,865,241,7533,180,117,0492,549,509,8572,489,145,2222,489,145,2212,077,023,5642,077,023,5632,030,233,4661,195,718,179899,848,459
Net income
0k
P
87,232,638102,480,874102,549,383101,063,984121,762,026117,914,668180,330,728110,838,005124,835,10173,436,7760-333,437,9710-317,882,092-452,046,675-650,130,6120
CFO
-26m
33,301,00523,514,8030056,077,731125,118,623179,347,7020154,662,019140,899,447139,837,80549,115,363-51,594,6010-25,872,471
Dividend
Jul 01, 20200.04 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chongqing Sansheng Industrial Co.,Ltd. is a Chinese enterprise specializing in the research, development, production, and sale of a diverse range of products, spanning both building materials and chemicals, as well as pharmaceuticals. Within its building materials and chemical segment, the company supplies essential construction inputs such as commercial concrete, water-reducing agents, and expansion agents. These products find extensive application across various large-scale infrastructure projects, including industrial and residential buildings, highways, railways, bridges, tunnels, airports, and water conservancy facilities. Additionally, Sansheng Industrial manufactures sulfuric acid, a key chemical component vital for the production of chemical fertilizers, general industrial chemicals, light industry products, textiles, steel, and water reducer formulations, among other non-fertilizer acidic compounds. The company also maintains a significant presence in the pharmaceutical sector. Its offerings here encompass pharmaceutical intermediates, exemplified by procaine hydrochloride, cefoxitin intermediate, chloramphenicol intermediate, aztreonam intermediate, and orlistat intermediate, which are crucial precursors for antibiotic drugs, anti-hepatitis C treatments, diabetes medications, specific penicillin variants, and cosmetic formulations. Furthermore, Sansheng produces active pharmaceutical ingredients (APIs) such as acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benoate, and diphenhydramine hydrochloride. Its range of finished pharmaceutical preparations includes compound paracetamol diphenhydramine, clarithromycin sustained-release, diclofenac sodium enteric-coated, and famotidine tablets, designed for diverse therapeutic applications like antipyretic and analgesic effects, antiviral, antibacterial, cough relief, allergy management, and local anesthesia. Beyond these, the company provides a selection of clinically significant drugs, including famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, and norfloxacin. Established in 2002, the company was initially known as Chongqing Sansheng Special Building Materials Co., Ltd. before officially adopting its current name, Chongqing Sansheng Industrial Co.,Ltd., in October 2016. Its operations are headquartered in Chongqing, China.
IPO date
Feb 17, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT